

(2) the humanized light chain variable region comprises three complementarity determining regions from the mouse M291 light chain and a framework from a human acceptor antibody light chain optionally having one or more human framework residues that interact with one of the CDRs substituted with mouse framework residues from corresponding positions in the M291 light chain variable region framework; and

the humanized antibody specifically binds to a CD3 antigen on the surface of T cells, wherein the mouse M291 antibody has a heavy chain with a variable region of sequence SEQ. ID. No. 11 and a light chain with a variable region of sequence SEQ. ID. No. 9.

<sup>34</sup>  
~~35~~ <sup>34</sup> The antibody of claim ~~34~~ which binds to a CD3 antigen on the surface of T cells with a binding affinity of at least  $10^7 M^{-1}$ .

<sup>35</sup>  
~~36~~ <sup>35</sup> The antibody of claim ~~35~~ which binds to a CD3 antigen on the surface of T cells with a binding affinity of at least  $10^8 M^{-1}$ .

<sup>34</sup>  
~~37~~ <sup>34</sup> The antibody of claim ~~37~~ which is of the IgG1 isotype.

<sup>34 35 36</sup>  
~~38~~ <sup>34 35 36</sup> The antibody of any one of claims ~~34~~, ~~35~~ or ~~36~~ wherein at least one of the light chain human framework residues that interact with one of the CDRs is substituted with a mouse amino acid from the corresponding position in the M291 light chain variable region framework.

<sup>34 35 36</sup>  
~~39~~ <sup>34 35 36</sup> The antibody of any one of claims ~~34~~, ~~35~~ or ~~36~~ wherein at least one of the heavy chain human framework residues that interact with one of the CDRs is substituted with a mouse amino acid from the corresponding position in the M291 heavy chain variable region framework.

40. The antibody of claim 39 wherein said position is selected from the group H30, H67, H68, H70, H72 and H74.

41. A humanized antibody that specifically binds to a CD3 antigen on the surface of T cells, comprising a pair of humanized heavy chains and humanized light chains, wherein the humanized light chain variable region comprises the amino acid sequence of Fig. 5A (upper lines) (SEQ. ID. No. 8) and the humanized heavy chain variable region comprises the amino acid sequence of Fig. 5B (SEQ. ID. No. 10)